Production (Stage)
Bolt Biotherapeutics, Inc.
BOLT
$5.94
$0.172.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -76.83% | -100.00% | -54.87% | -11.03% | 188.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -76.83% | -100.00% | -54.87% | -11.03% | 188.83% |
| Cost of Revenue | -40.87% | -28.18% | -7.80% | -1.35% | 6.32% |
| Gross Profit | 22.41% | 17.64% | -1.78% | 0.37% | 19.72% |
| SG&A Expenses | -34.47% | -28.66% | -34.05% | -13.29% | 3.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.37% | -28.30% | -15.10% | -4.51% | 10.50% |
| Operating Income | 29.12% | 20.73% | 9.57% | 4.03% | 7.18% |
| Income Before Tax | -2.12% | 10.99% | 6.65% | -17.38% | 36.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.12% | 10.99% | 6.65% | -17.38% | 36.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.12% | 10.99% | 6.65% | -17.38% | 36.33% |
| EBIT | 29.12% | 20.73% | 9.57% | 4.03% | 7.18% |
| EBITDA | 29.57% | 21.02% | 9.69% | 4.12% | 7.32% |
| EPS Basic | -1.41% | 11.79% | 7.59% | -16.22% | 36.97% |
| Normalized Basic EPS | 29.19% | 18.69% | 7.57% | 3.34% | 9.73% |
| EPS Diluted | -1.41% | 11.79% | 7.59% | -16.22% | 36.97% |
| Normalized Diluted EPS | 29.19% | 18.69% | 7.57% | 3.34% | 9.73% |
| Average Basic Shares Outstanding | 0.71% | 0.91% | 1.01% | 1.00% | 1.02% |
| Average Diluted Shares Outstanding | 0.71% | 0.91% | 1.01% | 1.00% | 1.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |